Eli Lilly's latest clinical data reveals that the combination of Taltz and Zepbound drives significant biomarker improvements in psoriasis patients, reinforcing the company's mid-term pipeline outlook.
Eli Lilly's stock is positively impacted by the TOGETHER-PsO study results, which demonstrate that combining Taltz and Zepbound leads to broader biomarker changes in psoriasis patients compared to Taltz monotherapy. This exploratory data, presented at Fall Clinical 2026, highlights the potential for expanded therapeutic efficacy and pipeline strength for two of Lilly's key growth drivers.
The study showed that the combination of Taltz and Zepbound resulted in broader biomarker changes in psoriasis patients as early as Week 12 compared to Taltz alone.
The findings were announced on October 9, 2026, and presented at the Fall Clinical 2026 conference.
Eli Lilly reported positive exploratory data from the TOGETHER-PsO study, demonstrating that combining Taltz and Zepbound yields broader biomarker changes in psoriasis patients. The findings, presented at Fall Clinical 2026, highlight the potential for enhanced therapeutic outcomes by Week 12.
The study showed that combining Taltz and Zepbound leads to broader biomarker changes in psoriasis patients compared to Taltz monotherapy, with results visible by Week 12.